Literature DB >> 20157721

Oligoclonal bands and MRI in clinically isolated syndromes: predicting conversion time to multiple sclerosis.

Rojas Juan Ignacio1, Patrucco Liliana, Cristiano Edgardo.   

Abstract

The objective of the study was to evaluate whether the presence of oligoclonal bands (OB) adds information in predicting CIS conversion to clinical definite multiple sclerosis (CDMS) and conversion time to CDMS. From 1998 to 2006, CIS patients were included in a prospective study. Patients underwent brain MRI and OB determination within 2 months of the first demyelinating event. We analyzed conversion to CDMS and time to conversion to CDMS according to abnormal MRI and the presence of OB. Forty patients were included. Fifteen patients (37%) converted to CDMS; 14 of them (93.3%) had abnormal baseline MRI (P = 0.01, RR = 5.9; 95% CI 1.3-10.1) and 13 (86.7%) had positive OB in CSF (P = <0.01, RR = 5.3; 95% CI 1.6-9.5). The risk of conversion to CDMS in patients with positive OB and abnormal baseline MRI was significantly higher compared to patients negative for both tests or with only one positive (RR = 9.1; 95% CI 3.5-14.6). Time to conversion to CDMS was 6.8 +/- 3.5 months for patients with OB and abnormal baseline MRI and 19 +/- 14 months for patients with only one abnormal test. CIS patients with abnormal baseline OB in CSF have a higher risk for developing CDMS. Regarding conversion time to CDMS, when abnormal MRI was added to positive OB, patients converted faster (mean time, 6 vs. 19 months). This information may be useful when considering treatment in CIS patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20157721     DOI: 10.1007/s00415-010-5490-y

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  11 in total

1.  Anaphylaxis to sesame.

Authors:  G B Pajno; G Passalacqua; G Magazzu; G Barberio; D Vita; G W Canonica
Journal:  Allergy       Date:  2000-02       Impact factor: 13.146

Review 2.  Environmental factors and multiple sclerosis.

Authors:  George C Ebers
Journal:  Lancet Neurol       Date:  2008-03       Impact factor: 44.182

3.  CSF analysis in suspected MS: do bands aid?

Authors:  Rogier Q Hintzen; Gavin Giovannoni
Journal:  Neurology       Date:  2008-03-25       Impact factor: 9.910

4.  Clinically isolated syndromes: a new oligoclonal band test accurately predicts conversion to MS.

Authors:  J Masjuan; J C Alvarez-Cermeño; N García-Barragán; M Díaz-Sánchez; M Espiño; M C Sádaba; P González-Porqué; J Martínez San Millán; L M Villar
Journal:  Neurology       Date:  2006-02-28       Impact factor: 9.910

5.  New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

Authors:  C M Poser; D W Paty; L Scheinberg; W I McDonald; F A Davis; G C Ebers; K P Johnson; W A Sibley; D H Silberberg; W W Tourtellotte
Journal:  Ann Neurol       Date:  1983-03       Impact factor: 10.422

6.  Baseline MRI predicts future attacks and disability in clinically isolated syndromes.

Authors:  M Tintoré; A Rovira; J Río; C Nos; E Grivé; N Téllez; R Pelayo; M Comabella; J Sastre-Garriga; X Montalban
Journal:  Neurology       Date:  2006-09-26       Impact factor: 9.910

Review 7.  Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.

Authors:  M Clerico; F Faggiano; J Palace; G Rice; M Tintorè; L Durelli
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

Review 8.  Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report.

Authors:  M Andersson; J Alvarez-Cermeño; G Bernardi; I Cogato; P Fredman; J Frederiksen; S Fredrikson; P Gallo; L M Grimaldi; M Grønning
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-08       Impact factor: 10.154

9.  Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?

Authors:  M Tintoré; A Rovira; J Río; C Tur; R Pelayo; C Nos; N Téllez; H Perkal; M Comabella; J Sastre-Garriga; X Montalban
Journal:  Neurology       Date:  2007-09-19       Impact factor: 9.910

10.  Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study.

Authors:  Ludwig Kappos; Mark S Freedman; Chris H Polman; Gilles Edan; Hans-Peter Hartung; David H Miller; Xavier Montalbán; Frederik Barkhof; Ernst-Wilhelm Radü; Lars Bauer; Susanne Dahms; Vivian Lanius; Christoph Pohl; Rupert Sandbrink
Journal:  Lancet       Date:  2007-08-04       Impact factor: 79.321

View more
  11 in total

1.  Optimizing outcomes in multiple sclerosis: consensus guidelines for the diagnosis and treatment of multiple sclerosis in Latin America.

Authors:  Adriana Carrá; Miguel Ángel Macías-Islas; Alberto Alan Gabbai; Jorge Correale; Carlos Bolaña; Eduardo Duriez Sotelo; Juan García Bonitto; Fernando Vergara-Edwards; Darwin Vizcarra-Escobar
Journal:  Ther Adv Neurol Disord       Date:  2011-11       Impact factor: 6.570

2.  Potential Biomarker and Therapeutic LncRNAs in Multiple Sclerosis Through Targeting Memory B Cells.

Authors:  Elahe Ghoveud; Shohreh Teimuri; Jafar Vatandoost; Aref Hosseini; Kamran Ghaedi; Masood Etemadifar; Mohammad Hossein Nasr Esfahani; Timothy L Megraw
Journal:  Neuromolecular Med       Date:  2019-10-01       Impact factor: 3.843

Review 3.  Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.

Authors:  Itay Raphael; Johanna Webb; Olaf Stuve; William Haskins; Thomas Forsthuber
Journal:  Expert Rev Clin Immunol       Date:  2014-12-18       Impact factor: 4.473

Review 4.  Biomarkers in Multiple Sclerosis.

Authors:  Anu Paul; Manuel Comabella; Roopali Gandhi
Journal:  Cold Spring Harb Perspect Med       Date:  2019-03-01       Impact factor: 6.915

Review 5.  Consensus opinion of US neurologists on practice patterns in RIS, CIS, and RRMS: Evolution of treatment practices.

Authors:  Carlo Tornatore; J Theodore Phillips; Omar Khan; Aaron E Miller; Mark Hughes
Journal:  Neurol Clin Pract       Date:  2016-08

6.  Risk of multiple sclerosis following clinically isolated syndrome: a 4-year prospective study.

Authors:  Roberto D'Alessandro; Luca Vignatelli; Alessandra Lugaresi; Elisa Baldin; Franco Granella; Maria Rosaria Tola; Susanna Malagù; Luisa Motti; Walter Neri; Massimo Galeotti; Mario Santangelo; Laila Fiorani; Enrico Montanari; Cinzia Scandellari; Maria Donata Benedetti; Maurizio Leone
Journal:  J Neurol       Date:  2013-02-03       Impact factor: 4.849

Review 7.  The evidence for a role of B cells in multiple sclerosis.

Authors:  G Disanto; J M Morahan; M H Barnett; G Giovannoni; S V Ramagopalan
Journal:  Neurology       Date:  2012-03-13       Impact factor: 9.910

8.  Clinically isolated syndromes suggestive of multiple sclerosis: an optical coherence tomography study.

Authors:  Celia Oreja-Guevara; Susana Noval; Juan Alvarez-Linera; Laura Gabaldón; Beatriz Manzano; Beatriz Chamorro; Exuperio Diez-Tejedor
Journal:  PLoS One       Date:  2012-03-20       Impact factor: 3.240

9.  No prognostic value of routine cerebrospinal fluid biomarkers in a population-based cohort of 407 multiple sclerosis patients.

Authors:  Madlyne Becker; Clotilde Latarche; Emilie Roman; Marc Debouverie; Catherine Malaplate-Armand; Francis Guillemin
Journal:  BMC Neurol       Date:  2015-05-13       Impact factor: 2.474

10.  Kappa free light chains: diagnostic and prognostic relevance in MS and CIS.

Authors:  Stefan Presslauer; Dejan Milosavljevic; Wolfgang Huebl; Silvia Parigger; Gabriele Schneider-Koch; Thomas Bruecke
Journal:  PLoS One       Date:  2014-02-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.